Regulation Text
Authority
5 U.S.C. 551-558,701-706;15 U.S.C. 1451-1461;21 U.S.C. 141-149,321-397,467f,679,821,1034;28 U.S.C. 2112;42 U.S.C. 201,262,263b,264.
Related Guidelines (10)
Best Practices for Communication Between IND Sponsors and FDA During Drug Development (Status: Final)
→Assessing User Fees Under the Generic Drug User Fee Amendments of 2017 Guidance for Industry (Status: Draft)
→Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP (Status: Final)
→Bundling Multiple Devices or Multiple Indications in a Single Submission: Guidance for Industry and FDA Staff (Status: Final)
→How to Write a Request for Designation (RFD): Guidance for Industry (Status: Final)
→Safety Labeling Changes -- Implementation of Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act (Status: Final)
→CVM GFI #79 Dispute Resolution Procedures for Science-Based Decisions on Products Regulated by CVM (Status: Final)
→Generic Drug User Fee Amendments of 2012: Questions and Answers Related to User Fee Assessments: Guidance for Industry (Status: Final)
→Postmarket Surveillance Under Section 522 of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry and Food and Drug Administration Staff (Status: Final)
→Safety Labeling Changes—Implementation of Section 505(o)(4) of the FD&C Act: Draft Guidance for Industry (Status: Draft)
→